The Markey Cancer Center (MCC) Protocol Review and Monitoring System (PRMS) provides thorough review of clinical trials for scientific validity, feasibility and prioritization within the clinical trials portfolio and monitoring of scientific progress. The PRMS must approve all interventional cancer research prior to study initiation and has the authority to recommend closure of trials for lack of scientific progress or patient accrual. The PRMS provides a framework which aims to balance appropriate resource utilization while maximizing the opportunities for current and future patients with cancer in this region to participate in clinical trials, including the underserved area of Appalachian Kentucky. The development of novel MCC investigator-initiated clinical trials and participation in high-priority national trials provide a robust portfolio of therapeutic research studies available to MCC patients.

Public Health Relevance

The patients of the MCC represent a diverse population with the highest incidence rates of lung and colorectal cancers in the United States, high rates of poverty and increased rates of important risk behaviors (i.e., smoking and low screening rates for some cancers). These challenges require a well-developed PRMS to facilitate effective clinical and translational trials to overcome the health disparities of this region and lead to improvement in cancer survival.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA177558-02
Application #
8740642
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Kentucky
Department
Type
DUNS #
City
Lexington
State
KY
Country
United States
Zip Code
40506
Chauhan, Aman; Farooqui, Zainab; Murray, Le Aundra et al. (2018) Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary. J Oncol 2018:3519247
Zhang, Xiaofei; Zhang, Yi; Han, Erik Y et al. (2018) Classification of Whole Mammogram and Tomosynthesis Images Using Deep Convolutional Neural Networks. IEEE Trans Nanobioscience 17:237-242
Li, Jing; Song, Jun; Li, Xian et al. (2018) FFAR4 Is Involved in Regulation of Neurotensin Release From Neuroendocrine Cells and Male C57BL/6 Mice. Endocrinology 159:2939-2952
Rodriguez, Sharon D; Vanderford, Nathan L; Huang, Bin et al. (2018) A Social-Ecological Review of Cancer Disparities in Kentucky. South Med J 111:213-219
Chauhan, Aman; Yu, Qian; Ray, Neha et al. (2018) Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget 9:19245-19254
Huang, Bin; Pollock, Elizabeth; Zhu, Li et al. (2018) Ranking composite Cancer Burden Indices for geographic regions: point and interval estimates. Cancer Causes Control 29:279-287
Rea, Matthew; Gripshover, Tyler; Fondufe-Mittendorf, Yvonne (2018) Selective inhibition of CTCF binding by iAs directs TET-mediated reprogramming of 5-hydroxymethylation patterns in iAs-transformed cells. Toxicol Appl Pharmacol 338:124-133
Yarana, Chontida; Carroll, Dustin; Chen, Jing et al. (2018) Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-Induced Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury. Clin Cancer Res 24:1644-1653
Banerjee, Moumita; Cui, Xiaoyu; Li, Zhichuan et al. (2018) Na/K-ATPase Y260 Phosphorylation-mediated Src Regulation in Control of Aerobic Glycolysis and Tumor Growth. Sci Rep 8:12322
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221

Showing the most recent 10 out of 359 publications